Skip to main content
    O

    Orchestra BioMed Holdings Inc. (OBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.74
    +0.10 (+1.77%)

    Market Cap: $338.99M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    73%(11/15)
    Avg Surprise
    +17.70%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.40
    Range$-0.45 - $-0.37
    6 analysts
    EPS Revisions
    1
    0
    7d
    1
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.38-4.6%
    60d ago$-0.38-4.6%
    30d ago$-0.41+1.5%
    7d ago$-0.400.0%
    Current$-0.40
    Revenue Consensus
    $103500
    Range$90000 - $141000
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.30
    Range$-0.43 - $-0.24
    6 analysts
    Revenue Consensus
    $68640
    Range$-4500 - $317500
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.30---
    Sep 26EST
    		-$-0.40---
    Jun 26
    Reported Aug 10
    		$-0.38$-0.35-8.57%Miss+24.0%
    Mar 26
    Reported May 12
    		$-0.33$-0.44+25.55%Beat+32.8%
    Dec 25
    Reported Mar 12
    		$0.26$-0.38+168.42%Beat+161.9%
    Sep 25
    Reported Nov 10
    		$-0.40$-0.43+6.98%Beat+2.4%
    Jun 25
    Reported Aug 12
    		$-0.50$-0.51+1.96%Beat-11.1%
    Mar 25
    Reported Apr 2
    		$-0.49$-0.48-2.08%Miss-28.9%
    Dec 24
    Reported Mar 26
    		$-0.42$-0.45+6.67%Beat-13.5%
    Sep 24
    Reported Nov 12
    		$-0.41$-0.44+6.82%Beat-7.9%
    Jun 24
    Reported Aug 12
    		$-0.45$-0.40-12.50%Miss-28.6%
    Mar 24
    Reported May 13
    		$-0.38$-0.38+0.00%Beat+5.0%
    Dec 23
    Reported Mar 27
    		$-0.37$-0.38+2.63%Beat-362.5%
    Sep 23
    Reported Nov 13
    		$-0.38$-0.39+2.56%Beat-660.0%
    Jun 23
    Reported Aug 10
    		$-0.35$-0.41+14.63%Beat-775.0%
    Mar 23
    Reported May 12
    		$-0.40$-0.28-42.86%Miss-1900.0%
    Dec 22
    Reported Jan 24
    		$-0.08N/A+95.32%Beat-1760.5%
    Sep 22
    Reported Dec 16
    		$-0.05$0.00N/AMiss-1036.4%
    Jun 22
    Reported Aug 15
    		$-0.04$0.00N/AMiss-788.9%
    Mar 22
    Reported May 13
    		$-0.02$0.00N/AMiss-100.0%
    Dec 21
    Reported Mar 31
    		$-0.00$0.00N/AMiss+57.0%
    Sep 21
    Reported Nov 12
    		$-0.00$0.00N/AMiss-37.5%
    Jun 21
    Reported Aug 16
    		$-0.00$0.00N/AMiss-
    Mar 21
    Reported Jun 29
    		$-0.01$0.00N/AMiss-
    Dec 20
    Reported Mar 30
    		$-0.01$0.00N/AMiss-
    Sep 20
    Reported Nov 5
    		$-0.00$0.00N/AMiss-
    Jun 20
    Reported Jul 17
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-6.76EV/EBITDAN/A
    Price/FCF-6.20xFCF Yield-16.14%
    Profitability
    Profit Margin-184.60%Operating Margin-25405.00%
    ROE-397.30%ROIC-83.30%
    Financial Health
    Debt/Equity1.83xInterest CoverageN/A
    Current Ratio8.26xQuick Ratio8.24x
    Trading Statistics
    Beta0.52Avg Volume318.59K
    52-Week High$6.5052-Week Low$3.26

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.82
    SMA 20$5.95
    SMA 50$5.48
    SMA 200$4.46
    EMA 10$5.82
    EMA 20$5.82
    EMA 50$5.47
    EMA 200$4.56

    MACD

    Line: 0.06Signal: 0.14Hist: -0.08

    ADX

    ADX: 21.9+DI: 17.1-DI: 19.9

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down88.0
    PSAR$6.11

    Bollinger Bands

    Upper Band$6.36
    Lower Band$5.55
    %B Position1360%(Upper)
    Band Width0.24

    RSI (14-Day)

    Neutral
    49.6

    Momentum Oscillators

    Stoch %K27.9
    Stoch %D33.8
    Williams %R-68.5
    ROC (10d)-9.6%
    Momentum-0.61
    CCI (20d)-85.8
    MFI (14d)44.5

    Volatility Measures

    ATR (14d)$0.33(5.8%)
    StdDev (20d)0.20
    Hist Vol47.6%(High)

    Volume Flow

    VWAP$5.75
    OBV18.7M
    AD Line-1.0M
    CMF (20d)0.066

    Volume Metrics

    Avg Vol (20d)315.0K
    Vol Ratio0.8x
    VWMA (20d)$6.00

    Pivot Points

    R3$6.04
    R2$5.95
    R1$5.79
    Pivot Point$5.70
    S1$5.54
    S2$5.45
    S3$5.29

    Advanced Oscillators

    TSI6.17
    Ultimate Osc57.0
    KST64.30

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$88,000$110,000$30.92M$861,000$836,000$868,000$253,000$987,000$778,000$620,000$262,000$419,000
    Cost of Revenue$25,000$32,000$51,000$49,000$46,000$44,000$58,000$68,000$44,000$34,000$47,000$41,000
    Gross Profit$63,000$78,000$30.87M$812,000$790,000$824,000$195,000$919,000$734,000$586,000$215,000$378,000
    Operating Expenses$22.42M$22.15M$24.11M$21.13M$20.12M$19.75M$16.87M$17.26M$17.59M$15.01M$12.70M$14.90M
    R&D$16.59M$15.78M$16.82M$14.03M$13.85M$13.48M$10.97M$11.60M$11.13M$9.11M$8.51M$8.56M
    SG&A$5.83M$6.37M$7.29M$7.10M$6.26M$6.26M$5.90M$5.67M$6.47M$5.90M$4.18M$6.34M
    Operating Income$-22,356,000$-22,076,000$6.75M$-20,313,000$-19,327,000$-18,921,000$-16,677,000$-16,342,000$-16,859,000$-14,423,000$-12,481,000$-14,524,000
    Interest Income$-1,768,000$1.42M$-763,000$-515,000$-36,000$166,000$522,000$916,000$879,000$971,000$2.64M$1.21M
    Interest Expense$1.40M$0$763,000$515,000$36,000$0$0$0$0$0$337,000$0
    Income Before Tax$-23,755,000$-20,691,000$5.99M$-20,828,000$-19,363,000$-18,755,000$-16,155,000$-15,426,000$-15,980,000$-13,463,000$-12,818,000$-13,316,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-23,755,000$-20,691,000$6.25M$-20,828,000$-19,363,000$-18,755,000$-16,155,000$-15,426,000$-15,980,000$-13,463,000$-12,818,000$-13,316,000
    EBITDA$-22,225,000$-22,034,000$6.58M$-20,503,000$-19,249,000$-18,904,000$-16,793,000$-16,622,000$-17,110,000$-14,949,000$-13,044,000$-15,480,000
    EBIT$-21,987,000$-22,111,000$6.75M$-20,313,000$-19,327,000$-18,921,000$-16,677,000$-16,342,000$-16,859,000$-14,434,000$-12,481,000$-14,524,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about OBIO

    News

    Piper Sandler reiterates Orchestra BioMed stock rating on AVIM trial

    Piper Sandler has reiterated an Overweight rating and a $12.00 price target for Orchestra BioMed (NASDAQ: OBIO) following the completion of enrollment for its pivotal AVIM therapy trial for hypertension. The firm...

    Investing.com•10/15/26•Bullish

    (OBIO) Risk Channels and Responsive Allocation

    This article analyzes Orchestra Biomed Holdings Inc. (NASDAQ: OBIO), highlighting weak near-term sentiment but potential long-term strength. It identifies elevated downside risk due to a lack of long-term support signals...

    Stock Traders Daily•10/8/26•Somewhat-Bearish

    Orchestra BioMed Completes Enrollment in Hypertension Trial

    Orchestra BioMed Holdings, Inc. has completed and exceeded enrollment in its pivotal BACKBEAT Global Pivotal Trial for a pacemaker-based hypertension therapy, conducted with Medtronic. The trial...

    MyChesCo•10/6/26•Bullish

    H.C. Wainwright reiterates Orchestra BioMed stock rating on trial enrollment

    H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for Orchestra BioMed Inc. (NASDAQ: OBIO) following the completion of enrollment in the company's pivotal hypertension trial. The BACKBEAT trial...

    Investing.com•10/5/26•Bullish

    Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO) and Regeneron (REGN)

    This article highlights bullish analyst ratings for two healthcare companies: Orchestra BioMed Holdings (OBIO) and Regeneron (REGN). Madison Elsaadi from B. Riley Securities reiterated a Buy rating for Orchestra BioMed...

    The Globe and Mail•10/3/26•Bullish

    OBIO Valuation and Fair Value

    P/E
    -6.8x
    P/FCF
    -6.2x
    P/B
    19.0x
    See GNG's fair value

    OBIO Profitability: Margins, ROIC and FCF

    Gross margin
    99.5%
    Operating margin
    -25405.0%
    Net margin
    -184.6%
    ROIC
    -83.3%
    ROE
    -397.3%
    FCF margin
    -184.8%
    FCF yield
    -16.1%

    OBIO Competitors

    CompanyTicker
    Opus Genetics, Inc.IRD
    Semler Scientific IncSMLR
    Embecta CorpEMBC
    Enanta Pharmaceuticals IncENTA
    Kyverna Therapeutics, Inc. Common StockKYTX
    Arcturus Therapeutics Holdings IncARCT
    Emergent Biosolutions IncEBS
    Sanara Medtech IncSMTI

    Sector: Healthcare

    OBIO Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    1
    Buy
    6
    Hold
    0
    Sell
    0
    Strong Sell
    0

    OBIO Bull Case vs Bear Case

    Bull case

    • OBIO beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 100.0% of OBIO's analyst ratings are Buy or Strong Buy.

    Bear case

    • OBIO has a -184.6% net profit margin.
    • OBIO's quarterly revenue changed -89.5% year over year.

    OBIO Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    25.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.40
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 2 down

    Frequently Asked Questions About OBIO

    Does OBIO pay dividends?

    Orchestra BioMed Holdings Inc. (OBIO) does not currently pay a regular dividend.

    What is OBIO's market cap?

    Orchestra BioMed Holdings Inc. (OBIO) has a market capitalization of $338.99M with a current stock price of $5.74.

    Related stocks

    Sector: Healthcare

    All stocks starting with O

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In